Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1)

Inclusion criteria

• ✓. Fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign the informed consent form (underage subjects must be signed by their guardians), and be able to cooperate with the tests required in various studies according to the protocol requirements;
• ✓. Aged 10 to 18 years old (including the critical value, subject to the time of signing the informed consent form), regardless of gender;
• ✓. Clinical diagnosis of Stargardt disease(STGD1), macular changes consistent with the clinical manifestations of Stargardt disease(STGD1);
• ✓. The biallelic ABCA4 pathogenic mutation has been confirmed by genetic testing and does not carry other pathogenic mutations for ophthalmic genetic diseases;
• ✓. The best corrected visual acuity of the study eye is ≤ETDRS 68 letters (20/50); the best corrected visual acuity of the fellow eye is ≥20/400.